ArticleEndocrine2026
lncRNA Gm10451 mediates β-cell functional impairment in type 1 diabetes through the miR-24-3p/G6PD axis.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPancreatic β-cell dysfunction underlies type 1 diabetes mellitus (T1DM) progression. Previous study showed that lncRNA Gm10451 is upregulated by high glucose and contributes to β-cell impairment, but its mechanism remains unclear.
methodsInteractions among Gm10451, miR-24-3p, and G6PD were validated by dual-luciferase assay and Ago2-RNA immunoprecipitation (Ago2-RIP). Expression was measured by RT-qPCR and Western blot. β-cell functions were evaluated by glucose-stimulated insulin secretion (GSIS), CCK-8, TUNEL, ELISA, and hyperglycemic clamp in 30 mM glucose-treated MIN6 cell and STZ-treated C57BL/6 mice (Control injected with citrate buffer).
resultsGm10451 was upregulated in diabetic models. Gm10451 acted as ceRNA to spomge miR-24-3p, which directly targeted G6PD. Overexpression of Gm10451 suppressed G6PD, aggravated oxidative/ER stress and inflammation, inhibited insulin secretion and promoted β-cell apoptosis. miR-24-3p mimic reversed these impairments.
conclusionGm10451 promotes β-cell dysfunction via the miR-24-3p/G6PD axis, representing a poteniall therapeutic target for diabetes-related β-cell dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.